Taho Pharmaceuticals Ltd.
Research Taho Pharmaceuticals Ltd. (6467.TW) on Bullrun: market cap TWD 11.16B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6467.TW
- ExchangeTW
- CountryTaiwan
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyTWD
- Market capTWD 11.16B
- Financial periodQ3 2026
- RevenueTWD 4.59M
- Net income-TWD 60.22M
- Free cash flow-TWD 49.73M
- Gross margin69.6%
Valuation Snapshot
latest market cap is TWD 11.16B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | TWD 8.41M | -TWD 214.40M | -TWD 210.04M | 64.3% | -4.16 | TWD 339.98M | TWD 11.31M | TWD 423.70M |
| FY2024 | TWD 0 | -TWD 167.44M | -TWD 165.73M | n/a | -3.69 | TWD 245.87M | TWD 16.65M | TWD 516.20M |
| FY2023 | TWD 1.07M | -TWD 120.68M | -TWD 107.10M | -6.8% | -3.12 | TWD 151.71M | TWD 21.62M | TWD 206.69M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-21 | TWD 11.16B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 TWD.
About Taho Pharmaceuticals Ltd.
Taho Pharmaceuticals Ltd., a commercial-stage pharmaceutical company, focuses on the development of drug delivery systems in transdermal and transmucosal systems in Taiwan. The company offers TAH4411 Ondansetron ODF, a selective serotonin 5HT3 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Its pipeline includes TAH3311 Apixaban oral film, which is in phase III; TAH3341, an anticoagulant apixaban ODF extended-release film, which is in preclinical stage.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Taho Pharmaceuticals Ltd.'s market cap?
Taho Pharmaceuticals Ltd.'s market capitalization is TWD 11.16B.
What does Taho Pharmaceuticals Ltd. do?
Taho Pharmaceuticals Ltd., a commercial-stage pharmaceutical company, focuses on the development of drug delivery systems in transdermal and transmucosal systems in Taiwan. The company offers TAH4411 Ondansetron ODF, a selective serotonin 5HT3 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Its pipeline includes TAH3311 Apixaban oral film, which is in phase III; TAH3341, an anticoagulant apixaban ODF extended-release film, which is in preclinical stage.